What is Labcorp?
Clinical laboratories and biopharma laboratory services company with $13.95B 2025 revenue scale and public-market buying capacity.
- Category
- Clinical laboratories and biopharma laboratory services
- Headquarters
- Burlington, NC
- Founded
- 1978
- Employees
- 67,000+
- Total funding
- Public company; no VC funding
- Status
- NYSE: LH; Public company
What is Labcorp?
Labcorp is a public clinical laboratories and biopharma laboratory services company headquartered in Burlington, NC. Labcorp's 2025 annual report showed approximately $13.95 billion of revenue, driven by Diagnostics and Biopharma Laboratory Services.
Labcorp operates in clinical laboratories and biopharma laboratory services with a portfolio that includes Routine clinical lab testing, Specialty testing, Central laboratory services, Early development services. Labcorp's 2025 annual report showed approximately $13.95 billion of revenue, driven by Diagnostics and Biopharma Laboratory Services. The company employs about 67,000+ and trades as NYSE: LH, so its buying motion looks like a regulated enterprise account rather than a startup account.
Its scale comes from clinically regulated products, payer or provider relationships, recurring consumables or services, intellectual property, manufacturing quality systems, and commercial access. Customers and partners evaluate Labcorp through clinical outcomes, regulatory execution, supply reliability, reimbursement, data security, and total cost of care.
For sellers, Labcorp is a multi-stakeholder account. Procurement, finance, clinical, quality, regulatory, legal, privacy, security, IT, operations, commercial, and business-unit leaders can all influence vendor approval. Strong pitches connect directly to patient impact, compliance, revenue capture, operating leverage, risk reduction, uptime, or measurable productivity.
What does Labcorp offer?
Labcorp offers products and services across Routine clinical lab testing, Specialty testing, Central laboratory services, Early development services and related healthcare workflows.
- Routine clinical lab testing· Diagnostics
- Specialty testing· Diagnostics
- Central laboratory services· Biopharma services
- Early development services· Biopharma services
- Patient service centers· Access network
- Digital health and results portals· Healthcare IT
How does Labcorp make money?
Labcorp earns revenue through regulated healthcare products, services, recurring consumables, software-enabled workflows, market access, and enterprise contracts.
Labcorp earns revenue from products and services sold to healthcare systems, clinicians, payers, labs, pharmacies, governments, distributors, life-science customers, or patients depending on the business line. In 2025, that model produced $13.95B 2025 of reported revenue scale. Growth is tied to product demand, procedure or test volumes, prescription access, installed-base utilization, new indications, geographic reach, and disciplined pricing.
Pricing is not a public self-serve tier. It is negotiated by therapy, device, test, payer coverage, account type, contract term, service level, GPO or distributor structure, reimbursement, and geography. The practical tiers are enterprise account segmentation, clinical evidence review, value-analysis committee approval, data/security review, legal terms, and renewal or tender economics.
Vendors should expect mature procurement and high evidence requirements. Budgets open when a proposal helps Labcorp improve launch execution, manufacturing resilience, clinical operations, data quality, regulatory readiness, patient access, field productivity, cybersecurity, or cost-to-serve.
Who leads Labcorp?
Labcorp is led by Adam Schechter, with finance, R&D, commercial, technology, medical, operations, and business-unit leaders shaping major enterprise decisions.
- Adam SchechterChairman and Chief Executive OfficerCEO since 2019Leads Labcorp's diagnostics and biopharma laboratory services strategy.
- Glenn EisenbergExecutive Vice President and Chief Financial OfficerCFO since 2014Oversees finance, capital allocation, and investor planning.
- Dr. Brian CaveneyPresident, Diagnostics and Chief Medical and Scientific OfficerSenior medical leaderLeads diagnostics and medical/scientific strategy.
- Lance BerberianExecutive Vice President and Chief Information and Technology OfficerTechnology leaderLeads technology, security, and digital operations.
How do you contact Labcorp's leadership?
Labcorp publishes official Labcorp investor-relations contact route, but it does not publish verified personal executive emails for the leaders listed here. Use the official investor, media, supplier, compliance, or contact form routes rather than guessed personal addresses.
official Labcorp investor-relations contact route; personal executive email format not verified- Glenn EisenbergExecutive Vice President and Chief Financial Officerofficial Labcorp investor-relations contact route
- Dr. Brian CaveneyPresident, Diagnostics and Chief Medical and Scientific Officerofficial Labcorp investor-relations contact route
How much funding has Labcorp raised?
Labcorp is a mature public company, not a venture-backed startup. It trades as NYSE: LH and funds growth through operating cash flow, public-market access, debt markets, partnerships, and acquisition capacity.
Labcorp's capital history is a public-company story rather than a disclosed venture-round history. The relevant funding events are founding, public listing, major acquisitions or divestitures, retained earnings, debt capacity, R&D reinvestment, manufacturing investment, and shareholder capital allocation.
As of June 2026, the current capital lens is NYSE: LH, $13.95B 2025 of 2025 revenue scale, and management's ability to fund launches, facilities, technology, clinical programs, supply chain, compliance, and business development. That is materially different from a startup where the next round controls hiring and tool budgets.
Seller signal: Labcorp has enterprise buying power, but budget access is tied to risk, ROI, auditability, executive sponsorship, and integration fit. Procurement is more likely to approve projects that reduce operational friction, protect regulated workflows, improve patient or customer outcomes, or support a named business priority.
How did Labcorp get here?
Labcorp grew through founding, product expansion, public-market scale, strategic portfolio moves, and regulated healthcare execution.
- 1978LabCorp predecessor incorporatedThe company traces roots to National Health Laboratories.
- 1995LabCorp formedNational Health Laboratories and Roche Biomedical Laboratories combine.
- 2015Covance acquisitionLabcorp expands deeply into drug-development services.
- 2023Fortrea spin-offLabcorp separates its clinical development CRO business.
- 2025$13.95B revenueLabcorp reports approximately $13.95 billion of 2025 revenue.
- 2026Guidance raisedLabcorp raises full-year 2026 revenue and adjusted EPS guidance after Q1.
Who are Labcorp's competitors?
Labcorp competes with large healthcare, pharma, diagnostics, life-science, and medtech companies that overlap in products, customers, procurement budgets, and clinical workflows.
- Quest DiagnosticsCompetes directly in national clinical labs, patient access, and payer contracts.
- IQVIACompetes in biopharma services, clinical development data, and pharma customer relationships.
- Charles River LaboratoriesCompetes in preclinical and drug-development services.
- Syneos HealthCompetes in clinical development and outsourced biopharma services.
- ICONCompetes in clinical research and central-lab-adjacent biopharma services.
- Exact SciencesCompetes in cancer diagnostics and specialty-testing demand.
Labcorp — frequently asked questions
